<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804856</url>
  </required_header>
  <id_info>
    <org_study_id>1230.4</org_study_id>
    <secondary_id>2008-003617-27</secondary_id>
    <nct_id>NCT00804856</nct_id>
  </id_info>
  <brief_title>Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia</brief_title>
  <official_title>An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The trial will be performed in two parts, a phase I part and a phase IIa part. In the phase I
      part of the trial, BI 6727 will be investigated as monotherapy and in combination with low
      dose cytarabine (LD-Ara-C) in patients with relapsed/refractory AML that are not eligible for
      intensive treatment. The dose of BI 6727 will be escalated to determine the maximum tolerated
      dose (MTD) of BI 6727 monotherapy and BI 6727 in combination with LD-Ara-C in AML patients.
      In the phase IIa part, the combination of BI 6727 at MTD with LD-Ara-C and LD-Ara-C
      monotherapy will be investigated to explore the efficacy of the combination schedule in
      comparison to LD-Ara-C monotherapy in previously untreated AML patients that are not eligible
      for intensive treatment.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 27, 2008</start_date>
  <completion_date type="Anticipated">July 11, 2018</completion_date>
  <primary_completion_date type="Actual">March 9, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I part: MTD of BI 6727 monotherapy and BI 6727 in combination with LDAraC</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase IIa part: Efficacy (complete remission, CR; complete remission with incomplete blood count recovery, CRi)</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence and intensity of adverse events graded according to CTCAE (version 3.0)</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic monitoring: drug effect on leukaemia cells</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial remission (PR)</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Remission duration</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc changes during and after intravenous infusion of BI 6727</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supportive care requirements (blood products, antibiotic usage, hospitalisation)</measure>
    <time_frame>minimum 4 weeks, maximum LPO</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BI 6727 when given alone and in combination with cytarabine: CL (Total Clearance of Volasertib in Plasma after i.v-Intravenous Administration) of BI 6727</measure>
    <time_frame>minimum 4 weeks, maximum 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of cytarabine after a single dose when given alone and in combination with BI 6727: Cmax, norm: dose normalized maximum measured concentration of cytarabine in plasma</measure>
    <time_frame>minimum 4 weeks, maximum 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of cytarabine after a single dose when given alone and in combination with BI 6727: dose normalized area under the concentration-time curve of cytarabine in plasma over the time interval from 0 extrapolated up to 4 hours</measure>
    <time_frame>minimum 4 weeks, maximum 8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of BI 6727 when given alone and in combination with cytarabine: VSS (Apparent Volume of Distribution at Steady State Following i.v.) of BI 6727</measure>
    <time_frame>minimum 4 weeks, maximum 8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Leukemia, Myeloid, Acute</condition>
  <arm_group>
    <arm_group_label>Schedule A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 6727 (d1 and 15 - one hour iv.) + LD ARA C 2x20 mg/d s.c.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BI 6727 (d1 and 15 - one hour iv.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Schedule C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>LD-ARA C monotherapy (2 x 20 mg/d s.c.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 6727 (d1 and 15)</intervention_name>
    <description>BI 6727 (d1 and 15 - one hour iv.v)</description>
    <arm_group_label>Schedule A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 6727 (d1 and 15)</intervention_name>
    <description>BI 6727 (d1 and 15 - one hour iv.v)</description>
    <arm_group_label>Schedule B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 2 x 20 mg/d s.c.</description>
    <arm_group_label>Schedule C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Cytarabine 2 x 20 mg/d s.c.</description>
    <arm_group_label>Schedule A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Male or female adult with relapsed/refractory AML ineligible for intensive treatment (phase
        I part only) Male or female adult with previously untreated AML ineligible for intensive
        treatment (phase IIa part only) Confirmed diagnosis of AML according to the WHO definition
        (except for acute promyelocytic leukaemia, APL) Patient is eligible for LD-Ara-C treatment
        Life expectancy &gt; 3 months Eastern co-operative oncology group (ECOG, R01-0787) performance
        score &lt;=2 at screening Signed written informed consent consistent with international
        conference on harmonisation, good clinical practice (ICH-GCP) and local legislation

        Exclusion criteria:

        Previously untreated AML (phase I part only) Relapsed or treatment refractory AML (phase
        IIa part only) Patient with APL (AML subtype M3 according to the French-American-British
        (FAB) classification) Hypersensitivity to one of the trial drugs or the excipients Other
        malignancy requiring treatment Symptomatic central nervous system involvement Clinically
        relevant QT prolongation (e.g. long QT syndrome, QTcF&gt;470 ms) Aspartate amino transferase
        (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal
        (ULN), or AST or ALT greater than 5 times the ULN in case of known leukaemia liver
        involvement Prothrombin time (PT) &gt; 1.5 x ULN for subjects not on therapeutic vitamin K
        antagonists (phenprocoumon, warfarin) Bilirubin greater than 1.5 mg/dl (&gt; 26 mcmol/L) Serum
        creatinine greater than 2.0 mg/dl Concomitant intercurrent illness, which would compromise
        the evaluation of efficacy or safety of the trial drug, e.g. active severe infection,
        unstable angina pectoris, cardiac arrhythmia or severe heart failure/cardiac insufficiency.

        Psychiatric illness or social situation that would limit compliance with trial requirements
        Concomitant therapy, which is considered relevant for the evaluation of the efficacy or
        safety of the trial drug Contraindications for cytarabine treatment according to the SPC
        Female patients of childbearing potential who are sexually active and unwilling to use a
        medically acceptable method of contraception during the trial, i.e. combination of two
        forms of effective contraception (hormonal contraception, intrauterine device, condom with
        spermicide, etc.).

        Male patients with partners of childbearing potential who are unwilling to use condoms in
        combination with a second medically acceptable method of contraception during the trial
        Pregnant or nursing female patients Patient unable to comply with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LKH-Univ. Klinikum Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV St-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Migration Data</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal General Hospital - McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Clémenceau, Hémato, Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP, Centre Hospitalier René Dubos, Hémato, Paris</name>
      <address>
        <city>Cergy Pontoise Cedex</city>
        <zip>95303</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Herriot</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTR, fondation Paschetta, Hémato, Nice</name>
      <address>
        <city>Nice Cedex 2</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Saint-Louis</name>
      <address>
        <city>Paris cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTR Henri Becquerel</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76088</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Campus Virchow-Klinikum, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>II. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Grande Ospedale Metropolitano Niguarda</name>
      <address>
        <city>Milano</city>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <zip>N-5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus HF, Ullevål sykehus</name>
      <address>
        <city>Oslo</city>
        <zip>N-0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

